Search Virginia Mason News
Promising New Hepatitis C Treatment Tested at Virginia Mason
Results of Phase 2 Trial of GS-7977 Presented at World Liver Congress in Spain
SEATTLE – (April 20, 2012) — There is new hope today for an effective treatment for more than 3 million Americans, and more than 120 million worldwide, who suffer from genotype 1 hepatitis C, the most common form of hepatitis C (HCV).
Kris Kowdley, MD, is the principal investigator for the Phase 2 trial of once-daily nucleotide GS-7977 from California-based Gilead Sciences. Dr. Kowdley is director of research and the Liver Center of Excellence at Virginia Mason’s Digestive Disease Institute. Several patients from Virginia Mason Medical Center in Seattle, Wash., participated in this trial.
According to the study, released yesterday at the World Liver Congress in Barcelona, Spain, GS-7977, when given in combination with PEG-IFN and ribavirin, proved effective in achieving a sustained virologic response (SVR) — meaning no detectable virus in the blood — in all patients in the trial after just 12 weeks of treatment, and in 90 percent of patients 12 weeks after treatment had ended.
The current approved treatment with PEG-IFN and ribavirin, in combination with either boceprevir or telaprevir given three times daily, has proven effective for 65-80 percent of previously untreated patients with genotype 1 hepatitis C, but also requires at least six months of treatment and has more side effects.
"The results suggest that this GS-7977-based regimen could offer most patients with genotype 1 a simple, short, three-month course of treatment with very high cure rates," said Dr. Kowdley, who presented the results yesterday in Barcelona. "An all-oral regimen for HCV remains the ultimate goal. In the interim, these results suggest that we may soon be able to end the current complex process and shorten the duration of treatment, which would be a significant advance for patients and for the physicians who manage their care."
Virginia Mason Medical Center and the Digestive Disease Institute are the recipient of America's 100 Best Specialty Excellence Award for Overall Gastrointestinal Care, ranked No. 1 in Washington State and in the top 5 percent in the nation for gastrointestinal services and medical treatment, and rated five-stars for Gastrointestinal Medical Treatment, Procedures and Surgeries, and for Treatment of Gastrointestinal Bleed, Bowel Obstruction and Pancreatitis by HealthGrades 2012.
Additional information about the Phase 2 trial of GS-7977, called ATOMIC, can be found at www.clinicaltrials.gov. GS-7977 is an investigational product and its safety and efficacy has not yet been established.
About Virginia Mason Medical Center
Virginia Mason Medical Center, founded in 1920, is a nonprofit regional health care system in Seattle that serves the Pacific Northwest. Virginia Mason employs more than 5,300 people and includes a 336-bed acute-care hospital; a primary and specialty care group practice of more than 450 physicians; satellite locations throughout the Puget Sound area; and Bailey-Boushay House, the first skilled-nursing and outpatient chronic care management program in the U.S. designed and built specifically to meet the needs of people with HIV/AIDS. Benaroya Research Institute at Virginia Mason is internationally recognized for its breakthrough autoimmune disease research. Virginia Mason was the first health system to apply lean manufacturing principles to health care delivery to eliminate waste and improve quality and patient safety.
Awards and distinctions include Top Hospital of the Decade by The Leapfrog Group, 2012 Top Hospital (for the sixth consecutive year) by The Leapfrog Group, 2012 Distinguished Hospital for Clinical Excellence from HealthGrades®, and 2012 America’s 100 Best Specialty Excellence Award for Overall Cardiac and Gastrointestinal Care from HealthGrades.
For media inquiries, contact:
(206) 341-1509 (o)
(206) 402-2822 (m)